[Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein]

Keita Fujikawa; Atsushi Kawakami; Katsumi Eguchi

[Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein]

Nihon Rinsho. 2007 Jul;65(7):1211-7.

[Article in Japanese]

Authors

Keita Fujikawa¹, Atsushi Kawakami, Katsumi Eguchi

Affiliation

¹ Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University.

PMID: 17642234

Abstract

TNF is a central cytokine in the pathogenesis of rheumatoid arthritis(RA), which induces synovitis as well as joint damage. Etanercept is a recombinant human soluble TNF receptor that binds specifically to TNF receptor, and inhibits TNF receptor-mediated signaling cascade. Recent investigations have revealed successful clinical efficacy of biologics in RA including etanercept. We reviewed here the structure and efficacy of etanercept in RA according to the published evidence.

Publication types

English Abstract
Review

MeSH terms

Antirheumatic Agents / chemistry
Antirheumatic Agents / pharmacology
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / etiology
Clinical Trials as Topic
Etanercept
Evidence-Based Medicine
Humans
Immunoglobulin G / chemistry
Immunoglobulin G / pharmacology
Immunoglobulin G / therapeutic use*
Receptors, Tumor Necrosis Factor / antagonists & inhibitors*
Receptors, Tumor Necrosis Factor / chemistry
Receptors, Tumor Necrosis Factor / physiology
Receptors, Tumor Necrosis Factor / therapeutic use

Substances

Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Etanercept